Immuron Update on IMM-124E SARS-CoV-2 Research
19 août 2022 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for...
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
26 juil. 2022 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American Travelan® Sales up 494% and Global sales up 431%
11 juil. 2022 06h00 HE
|
Immuron Limited
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11,...
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
07 juil. 2022 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
11 mai 2022 06h00 HE
|
Immuron Limited
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will focus on...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
09 mai 2022 06h00 HE
|
Immuron Limited
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the...
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer
05 mai 2022 20h22 HE
|
Immuron Limited
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Travelan® Global sales up 216%
27 avr. 2022 06h00 HE
|
Immuron Limited
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. ...
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
19 avr. 2022 07h33 HE
|
Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
Appointment of Paul Brennan as Non-Executive Director
16 mars 2022 09h30 HE
|
Immuron Limited
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...